.

BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

QuintilesIMS
Baxter
Moodys
Fish and Richardson
Mallinckrodt
Healthtrust
Harvard Business School
Citi
Federal Trade Commission
US Department of Justice

Generated: December 17, 2017

DrugPatentWatch Database Preview

Claims for Patent: 7,723,361

« Back to Dashboard

Claims for Patent: 7,723,361

Title:Methods for inhibiting undesired angiogenesis in patients having tumors with thalidomide
Abstract:The present invention comprises a group of compounds that effectively inhibit angiogenesis. More specifically, thalidomide and various related compounds such as thalidomide precursors, analogs, metabolites and hydrolysis products have been shown to inhibit angiogenesis and to treat disease states resulting from angiogenesis. Importantly, these compounds can be administered orally.
Inventor(s): D'Amato; Robert (Lancaster, PA)
Assignee: Celgene Corporation (Summit, NJ)
Application Number:11/096,155
Patent Claims: 1. A method for inhibiting undesired angiogenesis in a human having a blood born tumor comprising orally administering to said human a capsule comprising an angiogenesis-inhibiting amount of thalidomide and administering an amount of a compound that is an epoxide hydrolase inhibitor.

2. The method of claim 1 wherein the thalidomide is administered in an amount between approximately 0.1 and approximately 300 mg/kg/day.

3. The method of claim 2 wherein the thalidomide is administered in an amount between approximately 0.5 and 50 mg/kg/day.

4. The method of claim 3 wherein the thalidomide is administered in an amount between approximately 1 and approximately 10 mg/kg/day.

5. The method of claim 1 wherein the blood born tumor is leukemia.

6. The method of claim 1, wherein the epoxide hydrolase inhibitor is administered to said human together with thalidomide.

7. The method of claim 1, wherein the thalidomide and the epoxide hydrolase inhibitor are administered to said human sequentially.
« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Cerilliant
Fish and Richardson
Chinese Patent Office
Fuji
Julphar
Queensland Health
McKinsey
Accenture
UBS
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot